Seattle, WANCT07172659Now EnrollingIRB Ready

Leprosy Type 2 Reaction Clinical Trial in Seattle, WA

Access cutting-edge leprosy type 2 reaction treatment through this phase 2 clinical trial at a research site in Seattle. Study-provided care at no cost to qualified participants.

Sponsored by Medicines Development for Global Health

Quick Self-Assessment

See if you qualify for this Seattle location

Preparing your pre-screening questions…

Expert Care in Seattle

Access leprosy type 2 reaction specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related leprosy type 2 reaction treatment provided free

Apply for This Seattle Location

Check if you qualify for this leprosy type 2 reaction clinical trial in Seattle, WA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Seattle

    Convenient for WA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Seattle site if eligible
  4. 4Begin participation

About This Leprosy Type 2 Reaction Study in Seattle

Dovramilast has not been approved for leprosy type 2 reaction (erythema nodosum leprosum, ENL) or any other disease anywhere in the world. In this study, an experimental drug called dovramilast is being tested to see how it compares to current treatments for leprosy type 2 reaction. Specifically, this study aims to assess the efficacy of 100mg or 150 mg dovramilast compared with standard treatments (also known as standard of care). This study also aims to assess the safety of two strengths in ad

Sponsor: Medicines Development for Global Health

Who Can Participate

Inclusion Criteria

Aged 18 years of age or older.
Provision of written informed consent.
Laboratory confirmed previous or current Mycobacterium leprae or Mycobacterium lepromatosis infection.
Leprosy type 2 reaction meeting the following criteria:
Either: i. Acute (first episode and no treatment initiated) or ii. Recurrent (at least one further episode occurring 28 days or more after withdrawal of leprosy type 2 reaction treatment).
Presence of at least 10 leprosy type 2 reaction tender papular and/or nodular skin lesions (not including scars).
An ENLIST score of at least 9.
If a woman of reproductive potential, agree to the use of two reliable contraceptive measures (at least one of which is a highly effective form of contraception) from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care. Refer to Special Considerations for additional information.
If male (including those who have had a successful vasectomy), agree to using a latex condom during any sexual contact with women of reproductive potential from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care.

Exclusion Criteria

Chronic leprosy type 2 reaction, defined as the reaction occurring for 24 weeks or more during which a subject has required treatment either continuously or where any treatment free period had been \< 28 days.
Receipt of thalidomide, lenalidomide, pomalidomide, systemic corticosteroids, clofazimine (\> 50 mg/day), apremilast or any other phosphodiesterase (PDE) 4 inhibitor, or immunosuppressive/immunomodulatory treatment within 28 days of Baseline.
Receipt of an investigational agent within 28 days of Baseline or 5 half-lives of the investigational agent (whichever is longer).
Leprosy type 2 reaction with orchitis, uveitis, iritis, or severe neuritis (Grade 3 or greater severe neuritis).
Current diagnosis of leprosy type 1 reaction or Lucio's phenomenon.
Current tuberculosis, malaria, cutaneous or visceral leishmaniasis or other serious bacterial, viral, or parasitic infection at Screening or Baseline.
Active systemic fungal infection requiring or undergoing treatment.
Other than leprosy type 2 reaction, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.
Other than leprosy type 2 reaction, any other dermatological condition that could, in the opinion of the Investigator, interfere with the study assessments.
Chronic hepatitis B, chronic hepatitis C, or human immunodeficiency virus (HIV) positive.
Pregnant women or breastfeeding mothers.
Use (or planned use) of antimetabolites or alkylating agents, rifampin use more frequent than monthly, phenobarbital, carbamazepine, phenytoin, traditional or herbal preparations (including St. John's wort), foods (including grapefruit) known to affect activity of the cytochrome (CYP)3A4 enzyme; of all strong CYP3A and P-gp inhibitors including ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, ritonavir, cobicistat, diltiazem; and sensitive substrates of CYP3A4, CYP2C9, CYP2C19, and P-gp. Other CYP3A4, CYP2C9, CYP2C19, and P-gp non-sensitive substrates should be used with caution when concomitantly administered with dovramilast.
Known or suspected active substance abuse or a history of substance abuse within 6 months prior to Screening.
Prior history of suicide attempt at any time in the subject's lifetime prior to Screening or Randomization, or major psychiatric illness requiring hospitalization within the last 3 years.
Current diagnosis of depression, and/or history of suicide ideation
History of or presence of cardiac disease, including:
Clinically significant abnormal electrocardiogram
QTcF \> 450 msec
Receipt of a vaccination within 7 days of Baseline.
Known or suspected hypersensitivity to: PDE4 inhibitors including dovramilast or apremilast; thalidomide; prednisolone, or; excipients used in the formulation of dovramilast, thalidomide or prednisolone.
Body Mass Index \< 15 kg/m\^2 or \> 35 kg/m\^2.
Unable to, or significant difficulty with, swallowing tablets/capsules.
Anemia requiring transfusion.
History of or current pancreatitis.
Known or suspected cirrhosis of the liver.
The following laboratory abnormalities:
White blood cells (WBC) \< 2.5 x 10\^9/ L.
Neutrophils (granulocytes) \< 1.0 x 10\^9/L.
Platelets \< 80 x 10\^9/L.
Aspartate aminotransferase or alanine aminotransferase \> 2 times the upper limit of reference range.
Albumin \< 30 mg/dL.
Bilirubin \> 2 mg/dL
Calculated creatinine clearance (Cockcroft Gault) \< 50 milliliter (mL)/minute.
Lipase ≥ 1.6 times the upper limit
Previous participation in this study
Unwilling, unlikely or unable to comply with all protocol specified assessments, including photographic assessments
Enrolled in another leprosy type 2 reaction treatment study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Seattle?

Yes, this clinical trial (NCT07172659) has an active research site in Seattle, WA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Leprosy Type 2 Reaction Treatment Options in Seattle, WA

If you're searching for leprosy type 2 reaction treatment options in Seattle, WA, this clinical trial (NCT07172659) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Seattle research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced leprosy type 2 reaction specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all leprosy type 2 reaction clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Seattle, WA

See all pulmonary embolism clinical trials recruiting in Seattle — not just this study.

Browse Pulmonary Embolism Trials in Seattle →

Browse More Trials by Condition

Pulmonary Embolism TrialsAll Conditions →

Ready to Join in Seattle?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Seattle, WA